PegBio

PegBio is a biopharmaceutical company specializing in manufacturing polyethylene glycol and development of PEGylation technology leading to PEGylated drugs as putative NEW Molecule Entities. The Company currently provides reagent-grade mPEGs to its domestic and international customers in the academic and pharmaceutical fields. The mPEGs provided vary in molecular weights, structures, and a variety of activation groups such as succinimidyl succinate, succinimidyl carbonate, maleimide, and aldehyde. PegBio also provides PEGylation services by applying the random and site-specific technologies, to its strategic alliance collaborators for chemical modifications of macromolecules such as peptides, proteins, and antibody fragments. Among PegBio proprietary products, PEGylated peptides and antibody fragments for the treatment of type II diabetes and rheumatoid arthritis are being developed, respectively.